4-methoxy-2-(methylthio)pyrimidine | 76541-59-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-methoxy-2-(methylthio)pyrimidine
• 英文别名: 2-methylthio-4-methoxypyrimidine；4-Methoxy-2-methylthiopyrimidine；2,4-dimethyl-2-thiouracil；Pyrimidine, 4-methoxy-2-methylthio-；4-methoxy-2-methylsulfanylpyrimidine
• CAS: 76541-59-8
• 化学式: C₆H₈N₂OS
• mdl: MFCD00505930
• 分子量: 156.208
• InChiKey: GXCMABRXUXDVMW-UHFFFAOYSA-N

物化性质

• 熔点：
  32-33 °C(Solv: pentane (109-66-0))
• 沸点：
  264.1±13.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  60.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-methoxy-2-(methylthio)pyrimidine 在 盐酸 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 2.0h， 生成 2-Methylsulfanyl-6-thiophen-2-yl-5,6-dihydro-3H-pyrimidin-4-one
  参考文献：
  名称：

  A New Route to 5,6-Dihydropyrimidin-4(3H)-ones

  摘要：

  2,4-双（甲硫基）嘧啶或2,4-二甲氧基嘧啶与有机锂试剂的加成反应生成不稳定的6-取代2,4-双（甲硫基）-5,6-二氢嘧啶和2,4-二甲氧基-5,6-二氢嘧啶。对这些加成产物进行区域选择性水解可得到相应的6-取代2-甲硫基-5,6-二氢嘧啶-4（3H）酮和6-取代2-甲氧基-5,6-二氢嘧啶-4（3H）酮。甲氧基产物可以进一步水解为6-取代二氢尿嘧啶。

  DOI：

  10.1055/s-1987-28013
• 作为产物：
  描述：

  2-甲硫基-4-嘧啶酮 在 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 20.0h， 生成 4-methoxy-2-(methylthio)pyrimidine
  参考文献：
  名称：

  Alkylated 2- and 4-Thiouracils. Syntheses and HPLC Separations.

  摘要：

  DOI：

  10.3891/acta.chem.scand.36b-0015

文献信息

• Aminopyrimidine Kinase Inhibitors
  申请人：Baldino Carmen M.

  公开号：US20110152235A1

  公开（公告）日：2011-06-23

  Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.

  揭示了化合物、含有这些化合物的药物组合物，以及这些化合物和组合物作为酪蛋白激酶1（例如CK1γ）、酪蛋白激酶2（CK2）、Pim 1、Pim2、Pim3、TGFβ途径、Wnt途径、JAK/STAT途径和/或mTOR途径调节剂的用途。还揭示了用于治疗或预防一系列治疗适应症的用途，至少部分原因是由于酪蛋白激酶1（例如CK1γ）、酪蛋白激酶2（CK2）、Pim 1、Pim2、Pim3、TGFβ途径、Wnt途径、JAK/STAT途径和/或mTOR途径的异常生理活性。
• Methyl Orthocarboxylates as Methylating Agents of Heterocycles
  作者：Yves L. Janin、Christiane Huel、Geneviève Flad、Sylvie Thirot

  DOI：10.1002/1099-0690(200206)2002:11<1763::aid-ejoc1763>3.0.co;2-q

  日期：2002.6

  rearrangement into, mostly, 1-methylpyridin-2(1H)-one was studied. The new techniques described here (methanol trapping with 4 A molecular sieves and Lewis acid-catalyzed reaction) greatly increase the potential of trimethyl orthocarboxylates. These reagents can be considered as possible alternatives to the dimethyl formamide-producing N,N-dimethylformamide dimethyl acetal and may sometimes be attractive

  作为经典甲基化方法的替代方法，研究了原羧酸三甲酯或 N，N-二甲基甲酰胺二甲基缩醛与各种羟基化杂环之间发生的甲基化反应，涉及内酰胺-内酰胺互变异构平衡。相应的 O-甲基化或 N-甲基化化合物在许多情况下被分离出来，反应的区域选择性有时会跟随，有时与使用标准甲基化方法的相应结果不同。在这项工作的过程中，注意到了以前未报告的影响。在一种情况下，使用甲苯作为反应溶剂会产生更多的 N-甲基化物质。在其他情况下，试剂的空间体积和/或稳定性的影响（原甲酸酯与原乙酸酯或 N,N-二甲基甲酰胺二甲基缩醛与 其乙酰胺同系物）也被注意到。有时可以避免不需要的甲酰化反应，并且在较少情况下观察到 O-甲基化物质的增加。先前未报道的 1-dimethoxymethylpyridin-2(1H)-one 被表征，并研究了其酸催化重排成，主要是 1-methylpyridin-2(1H)-one。这里描述的新技术（用 4
• 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS
  申请人：Aicher Thomas D.

  公开号：US20090156603A1

  公开（公告）日：2009-06-18

  Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了化学式I的化合物，这些化合物在治疗和/或预防由胰岛素活性不足引起的疾病中非常有用，例如糖尿病。还提供了治疗或预防由胰岛素活性不足或可以通过激活胰岛素来治疗的疾病和疾患的方法。
• COMPOUNDS 563
  申请人：FORSBLOM Rickard

  公开号：US20100130495A1

  公开（公告）日：2010-05-27

  The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which inhibit the Aβ40 and Aβ42 production, increase the Aβ37 and Aβ38 production and maintain the Notch signaling and will be used for treatment and/or prevention of Aβ-related pathologies such as Alzheimer's disease, Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及公式I的新化合物及其治疗上可接受的盐，它们的制药组合物，制备它们的方法以及它们作为治疗和/或预防各种疾病的治疗方法。特别是本发明涉及抑制Aβ40和Aβ42产生，增加Aβ37和Aβ38产生并维持Notch信号的化合物，并将其用于治疗和/或预防与Aβ相关的病理，如阿尔茨海默病，唐氏综合症和β-淀粉样蛋白血管病，如但不限于脑淀粉样血管病，遗传性脑出血，与认知功能障碍相关的疾病，如但不限于轻度认知障碍（MCI），阿尔茨海默病，记忆力丧失，与阿尔茨海默病相关的注意力缺陷症状，与阿尔茨海默病或痴呆症相关的神经退行性疾病，包括混合性血管性和退行性起源的痴呆，早老性痴呆，老年性痴呆以及与帕金森病，进行性核上性麻痹或皮层基底节变性相关的痴呆。
• Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
  申请人：Aicher Thomas Daniel

  公开号：US20100204240A1

  公开（公告）日：2010-08-12

  Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  提供的化合物式(I)如下：其中R2、R3、R13、L和D2如规范中所定义，这些化合物可用于治疗和/或预防由于葡萄糖激酶活性不足引起或可以通过激活葡萄糖激酶治疗的疾病或紊乱，包括但不限于糖尿病、糖耐量受损、IFG（空腹血糖受损）和IFG（空腹高血糖），以及本文所讨论的其他疾病和紊乱。